Dyne Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 235.94 million compared to USD 168.1 million a year ago. Basic loss per share from continuing operations was USD 3.95 compared to USD 3.23 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26 USD | +0.19% | -0.31% | +95.49% |
May. 02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+95.49% | 2.27B | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Dyne Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023